Table 1.
Demographic and baseline clinical characteristics distribution.
| No. | % | |
|---|---|---|
| Sex | ||
| Male | 31 | 59.6% |
| Female | 21 | 40.4% |
| Age, years | ||
| Median (range) | 57.5 (24–69) | |
| Mean (SD) | 54.3 (9.9) | |
| Clinical T stage | ||
| T2 | 2 | 3.8% |
| T3a | 18 | 34.6% |
| T3b | 15 | 28.8% |
| T3c | 4 | 7.7% |
| T4a | 6 | 11.5% |
| T4b | 7 | 13.5% |
| Clinical N stage | ||
| N0 | 2 | 3.8% |
| N1 | 22 | 42.3% |
| N2a | 12 | 23.1% |
| N2b | 16 | 30.8% |
| MRF | ||
| Negative | 32 | 61.5% |
| Positive | 20 | 38.5% |
| Location from anal verge, cm | ||
| Median (range) | 4.8 (1.6–11) | |
| Mean (SD) | 4.8 (1.8) | |
| Length of the tumour, cm | ||
| Median (range) | 5.1 (2.7–11.4) | |
| Mean (SD) | 5.4 (1.9) | |
| CEA | ||
| Normal | 33 | 63.5% |
| Abnormal | 18 | 34.6% |
| Missing | 1 | 1.9% |
| CA19-9 | ||
| Normal | 34 | 65.4% |
| Abnormal | 16 | 30.8% |
| Missing | 2 | 3.8% |
| Total | 52 | 100.0% |
CEA, carcinoembryonic antigen; MRF, mesorectal fascia; SD, standard deviation.